Anovulation with or without PCO, hyperandrogenaemia and hyperinsulinaemia as promoters of endometrial and breast cancer

被引:28
作者
Papaioannou, Spyros [1 ]
Tzafettas, John [2 ]
机构
[1] Univ Birmingham, Heartlands Hosp, Heart England NHS Fdn Trust, Birmingham B9 5SS, W Midlands, England
[2] Aristotle Univ Thessaloniki, Dept Obstet & Gynecol 2, Hippokrat Gerneral Hosp, Thessaloniki 54642, Greece
关键词
breast cancer; endometrial cancer; hyperandrogenaemia; hyperinsulinaemia; obesity; PCO; polycystic ovaries; metabolic syndrome; POLYCYSTIC-OVARY-SYNDROME; STEIN-LEVENTHAL SYNDROME; HORMONE-REPLACEMENT THERAPY; POSTMENOPAUSAL WOMEN; PROSPECTIVE COHORT; YOUNG-WOMEN; REPRODUCTIVE FACTORS; INSULIN-RESISTANCE; METABOLIC SYNDROME; FAT DISTRIBUTION;
D O I
10.1016/j.bpobgyn.2008.11.010
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
The relationship of infertility, endocrinology and cancer has become clearer in recent years. Polycystic ovaries (PCO) increase the risk of endometrial cancer. Prolonged amenorrhoea, therefore, should be prevented in such cases with the use of cyclical progestogens, in order for regular withdrawal bleeds to be induced and the endometrium protected from long-term unopposed oestrogen stimulation. There is no secure evidence base on which a relationship between PCO and breast cancer can be based. No specific breast screening for women with PCO is, therefore, recommended. Flyperandrogenaemia and hyperinsulinaemia are conditions whose significance in terms of increasing both endometrial and breast cancer risks is increasingly recognised. The exact mechanism with which they influence carcinogenesis is still far from clear. Whether they act in isolation or as expressions of the common background of the metabolic syndrome - in inter-action with other components of this syndrome - is still the subject of research. (C) 2009 Elsevier Ltd. All rights reserved.
引用
收藏
页码:19 / 27
页数:9
相关论文
共 63 条
[1]  
Anderson KE, 1997, CANCER, V79, P494, DOI 10.1002/(SICI)1097-0142(19970201)79:3<494::AID-CNCR10>3.0.CO
[2]  
2-Z
[3]   Polycystic ovary syndrome and cancer [J].
Balen, A .
HUMAN REPRODUCTION UPDATE, 2001, 7 (06) :522-525
[4]   Diagnosis and therapy of hyperandrogenism [J].
Barnes, RB .
BAILLIERES CLINICAL OBSTETRICS AND GYNAECOLOGY, 1997, 11 (02) :369-396
[5]   Breast cancer and breastfeeding: collaborative reanalysis of individual data from 47 epidemiological studies in 30 countries, including 50 302 women with breast cancer and 96 973 women without the disease [J].
Beral, V ;
Bull, D ;
Doll, R ;
Peto, R ;
Reeves, G ;
La Vecchia, C ;
Magnusson, C ;
Miller, T ;
Peterson, B ;
Pike, M ;
Thomas, D ;
van Leeuwen, F .
LANCET, 2002, 360 (9328) :187-195
[6]  
Beral Valerie, 2003, Lancet, V362, P419
[7]  
BRYAN RM, 1984, CANCER-AM CANCER SOC, V54, P2436, DOI 10.1002/1097-0142(19841201)54:11<2436::AID-CNCR2820541121>3.0.CO
[8]  
2-H
[9]  
CHAMLIAN DL, 1970, OBSTET GYNECOL, V36, P659
[10]   Differential effects of reproductive factors on the risk of pre- and postmenopausal breast cancer. Results from a large cohort of French women [J].
Clavel-Chapelon, F .
BRITISH JOURNAL OF CANCER, 2002, 86 (05) :723-727